Rineterkib
- Generic Name
- Rineterkib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27BrF3N5O2
- CAS Number
- 1715025-32-3
- Unique Ingredient Identifier
- 15KFN616FK
- Background
Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT04417621
- Locations
- πΊπΈ
The Angeles Clinic and Research Institute, Los Angeles, California, United States
πΊπΈFlorida Cancer Specialists, Fort Myers, Florida, United States
πΊπΈH Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
- Conditions
- BRAF V600 Colorectal Cancer
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04294160
- Locations
- πΊπΈ
University of California LA Santa Monica Location, Los Angeles, California, United States
πΊπΈMassachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈSarah Cannon Research Institute SC, Nashville, Tennessee, United States
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT04097821
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
- Conditions
- Non-Small Cell Lung CancerMelanoma
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 241
- Registration Number
- NCT02974725
- Locations
- πΈπͺ
Novartis Investigative Site, Stockholm, Sweden
πΊπΈUni of TX MD Anderson Cancer Cntr, Houston, Texas, United States
πΊπΈSarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee, United States
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
- Conditions
- Ovarian NeoplasmsNon-Small-Cell Lung CarcinomaMelanomaOther Solid Tumors
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT02711345
- Locations
- π¨π
Novartis Investigative Site, Bellinzona, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.